echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Approved: 800 million vitamin varieties! Zhengda Pharmaceuticals won the first review

    Approved: 800 million vitamin varieties! Zhengda Pharmaceuticals won the first review

    • Last Update: 2021-03-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A few days ago, the official website of the State Drug Administration shows that Zhengda Pharmaceutical (Qingdao) Afa osteotisol softgels to supplement the application was approved, is the first domestic product evaluation enterprises.
    2018 sales of Afa osteobolic alcohol capsules in China's public medical institutions exceeded 800 million yuan, a slight decline in 2019, according to the Company's internal network data.
    first half of 2020, Afa orthool softgels with 5.70% market share among the vitamin products TOP5.
    January 29, 2021 drug approval documents to be received information release-1 data show that alfa osteotisol is an active vitamin D, mainly used for osteoporosis, adrenal osteopathy, thyroid side gland hypertension and other adaptive disorders.
    Source: One-click access to Minet data show that in 2018, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of Afa osteool capsules exceeded 800 million yuan, a slight decline in 2019.
    In the first half of 2020, Afa orthopedicol softgels with 5.70% market share among the vitamin products TOP5, domestic manufacturers have Kunming Baker Norton Pharmaceuticals, Shanghai Xinyi Yan'an Pharmaceuticals and other 6 import manufacturers have Teva Pharmaceuticals and Leo.
    the evaluation of consistency, at present, Kunming Baker Norton Pharmaceuticals and Shanghai Xinyi Yan'an Pharmaceutical Co., Ltd. in the evaluation of supplementary applications in the review and approval (in the drug review center).
    source: official website of the State Drug Administration, Mi Net database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.